AgeX Therapeutics, Inc. entered into a Fourth Amendment to the Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited, extending the deadline for fulfillment of the Reverse Financing Condition and allowing Juvenescence to convert the outstanding amount of the loans into AgeX common stock without restriction by the 19.9% Cap.